Source snapshot Publisher wording captured Jul 22, 2026, 12:36 PM 554 normalized characters retained in this legacy snapshot; capture completeness was not recorded. Public display is limited to an excerpt.

BOLD.news versionRead the distilled report

business

Trump's generic drugs tariff threatens Indian pharma's top market

Nikkei Asia reporting 5 sentences analyzed 552 captured characters

100% levy from 2028 could accelerate push into higher value medicines

The U.S. accounted for about 37% of India's nearly $26 billion in pharma exports in 2025, the Global Trade Research Initiative estimates. © Reuters

BENGALURU -- Washington's move to put a 100% tariff on generic drug imports threatens the access of India's pharmaceutical industry to its largest market while upping the pressure to expand into higher-value medicines, with shares of several drugmakers sliding on fears that shifting production to the U.S. would be a gargantuan task.

BOLD.news retains normalized extraction for time-stamped evidence and analysis. This public wrapper shows a limited excerpt because availability is not a republication license; use the publisher link for the complete presentation.